View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2019	Nov. 14, 2019
Document Information [Line Items]
Entity Registrant Name	Predictive Oncology Inc.
Entity Central Index Key	0001446159
Trading Symbol	poai
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		3,887,956
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common Stock, $0.01 par value

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current Assets:
Cash and Cash Equivalents	$ 98,599	$ 162,152
Accounts Receivable	372,119	232,602
Notes Receivable (inclusive of $0 and $452,775 in advances to Helomics; net of $787,524 and $0 in allowance for credit losses)	250,000	497,276
Inventories	210,350	241,066
Prepaid Expense and other assets	131,558	318,431
Total Current Assets	1,062,626	1,451,527
Notes Receivable		1,112,524
Fixed Assets, net	1,633,750	180,453
Intangibles, net	4,508,433	964,495
Lease Right-of-Use Assets	886,712
Goodwill	23,790,290
Total Assets	31,881,811	3,708,999
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts Payable	3,762,468	445,689
Notes Payable –Net of Discounts of $499,215 and $1,032,814	4,470,380	1,634,914
Accrued Expenses	1,807,188	1,279,114
Derivative Liability	210,762	272,745
Deferred Revenue	30,638	23,065
Lease Liability – Net of Long-term Portion	500,732
Total Current Liabilities	10,782,168	3,655,527
Lease Liability	385,980
Total Liabilities	11,168,148	3,655,527
Stockholders’ Equity:
Common Stock, $.01 par value, 100,000,000 shares authorized, 3,149,751 and 1,409,175 outstanding	31,497	14,092
Additional paid-in capital	89,590,908	63,146,533
Accumulated Deficit	(68,944,537)	(63,107,945)
Total Stockholders' Equity	20,713,663	53,472
Total Liabilities and Stockholders' Equity	31,881,811	3,708,999
Series E Convertible Preferred Stock [Member]
Stockholders’ Equity:
Convertible Preferred Stock	3
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Convertible Preferred Stock	792	792
Series D Convertible Preferred Stock [Member]
Stockholders’ Equity:
Convertible Preferred Stock	$ 35,000

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Notes receivable	$ 250,000	$ 497,276
Reserve for bad debt	787,524	0
Discount of note payable	$ 499,215	$ 1,032,814
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares outstanding (in shares)	3,149,751	1,409,175
Series E Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	350	350
Preferred stock, shares outstanding (in shares)	257.7	0
Preferred stock, liquidation value	$ 2,577,000	$ 2,577,000
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	79,246	79,246
Series D Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	3,500,000	0
Helomics Holding [Member]
Notes receivable	$ 0	$ 452,775

Condensed Consolidated Statements of Net Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue	$ 522,696	$ 329,930	$ 1,064,088	$ 1,100,108
Cost of goods sold	208,096	83,006	400,202	309,320
Gross margin	314,600	246,924	663,886	790,788
General and administrative expense	2,616,991	762,603	7,425,305	2,708,274
Operations expense	707,414	723,939	2,445,238	1,390,434
Sales and marketing expense	434,955	621,465	1,674,200	1,726,087
Total operating loss	(3,444,760)	(1,861,083)	(10,880,857)	(5,034,007)
Gain on revaluation of cash advances to Helomics			1,222,244
Other income	15,084		65,293
Other expense	578,836		1,967,895
Loss on equity method investment		645,786	439,637	1,606,294
Gain on revaluation of equity method investment			6,164,260
Net loss	(4,008,512)	(2,506,869)	(5,836,592)	(6,640,301)
Deemed dividend on Series E Convertible Preferred Stock	125,801		146,199
Net loss attributable to common shareholders per common shares – basic and diluted	$ (4,134,313)	$ (2,506,869)	$ (5,982,791)	$ (6,640,301)
Loss per common share - basic and diluted (in dollars per share)	$ (1.31)	$ (1.89)	$ (2.32)	$ (5.45)
Weighted average shares used in computation - basic and diluted (in shares)	3,146,609	1,325,261	2,581,014	1,217,829

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Private Placement [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member]	Common Stock [Member] Series E Warrants [Member]	Common Stock [Member] Re-priced Warrants [Member]	Common Stock [Member] Private Placement [Member]	Common Stock [Member] Over-Allotment Option [Member]	Common Stock [Member] Chief Executive Officer [Member]	Common Stock [Member] Bridge Notes [Member]	Common Stock [Member] Helomics Acquisition, Inc. [Member]	Common Stock [Member] Consulting Agreement One [Member]	Common Stock [Member] Contract with TumorGenesis [Member]	Common Stock [Member] TumorGenesis [Member]	Common Stock [Member]	Additional Paid-in Capital [Member] Series E Warrants [Member]	Additional Paid-in Capital [Member] Re-priced Warrants [Member]	Additional Paid-in Capital [Member] Warrants Issued to CEO [Member]	Additional Paid-in Capital [Member] Expense Warrant for Note Extension [Member]	Additional Paid-in Capital [Member] Warrant for Promissory Notes [Member]	Additional Paid-in Capital [Member] Warrants Issued to Helomics' Investors [Member]	Additional Paid-in Capital [Member] Warrants Held by Noteholders [Member]	Additional Paid-in Capital [Member] Private Placement [Member]	Additional Paid-in Capital [Member] Over-Allotment Option [Member]	Additional Paid-in Capital [Member] Chief Executive Officer [Member]	Additional Paid-in Capital [Member] Bridge Notes [Member]	Additional Paid-in Capital [Member] Helomics Acquisition, Inc. [Member]	Additional Paid-in Capital [Member] Consulting Agreement One [Member]	Additional Paid-in Capital [Member] Contract with TumorGenesis [Member]	Additional Paid-in Capital [Member] TumorGenesis [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member] Over-Allotment Option [Member]	Retained Earnings [Member]	Series E Convertible Preferred Stock [Member]	Series E Warrants [Member]	Re-priced Warrants [Member]	Warrants Issued to CEO [Member]	Expense Warrant for Note Extension [Member]	Warrant for Promissory Notes [Member]	Warrants Issued to Helomics' Investors [Member]	Warrants Held by Noteholders [Member]	Private Placement [Member]	Over-Allotment Option [Member]	Chief Executive Officer [Member]	Bridge Notes [Member]	Helomics Acquisition, Inc. [Member]	Consulting Agreement One [Member]	Contract with TumorGenesis [Member]	TumorGenesis [Member]	Total
Balance (in shares) at Dec. 31, 2017	79,246				647,819											694,328
Balance at Dec. 31, 2017	$ 792				$ 6,479											$ 6,943																$ 57,442,745		$ (54,765,045)																	$ 2,691,914
Warrant exercises (in shares)						14,539	50,467
Warrant exercises						$ 145	$ 505										$ 145,251	$ 504,160																		$ 145,396	$ 504,665
Shares issued for services (in shares)																25,000
Shares issued for services																$ 250																294,750																			295,000
Shares issued in escrow pursuant to a contract with TumorGenesis at $11.70 per share (in shares)															75,000
Shares issued in escrow pursuant to a contract with TumorGenesis at $11.70 per share															$ 750																$ 876,750																			$ 877,500
Stock issuable for bridge loan																											$ 206,605																			$ 206,605
Warrants issued per bridge loan																																143,707																			143,707
Vesting Expense																																800,322																			800,322
Net loss																																		(6,640,301)																	(6,640,301)
Preferred conversion to common shares pursuant to private placement agreement (in shares)				(647,819)				58,975
Preferred conversion to common shares pursuant to private placement agreement				$ (6,479)				$ 590																$ 5,889																											(6,479)
Shares issued (in shares)									21,525							290,000
Shares issued									$ 215							$ 2,900									$ 204,206							2,752,187												$ 204,422							2,755,087
Shares issued for acquisition (in shares)												110,000
Shares issued for acquisition												$ 1,100																$ 1,041,150																			$ 1,042,250
Shares issued																																	$ 1
Balance (in shares) at Sep. 30, 2018	79,246															1,339,834
Balance at Sep. 30, 2018	$ 792															$ 13,398																64,417,722		(61,405,345)																	3,026,567
Balance (in shares) at Jun. 30, 2018	79,246															1,208,945
Balance at Jun. 30, 2018	$ 792															$ 12,089																62,247,373		(58,898,476)																	3,361,778
Warrant exercises (in shares)						5,656	25,233
Warrant exercises						$ 57	$ 252										$ 56,503	$ 252,080																		$ 56,560	$ 252,332
Shares issued for services (in shares)													25,000
Shares issued for services													$ 250																$ 294,750																			$ 295,000
Shares issued in escrow pursuant to a contract with TumorGenesis at $11.70 per share (in shares)														75,000
Shares issued in escrow pursuant to a contract with TumorGenesis at $11.70 per share														$ 750																$ 876,750																			$ 877,500
Stock issuable for bridge loan																																206,605																			206,605
Warrants issued per bridge loan																																143,707																			143,707
Vesting Expense																																339,954																			339,954
Net loss																																		(2,506,869)																	(2,506,869)
Balance (in shares) at Sep. 30, 2018	79,246															1,339,834
Balance at Sep. 30, 2018	$ 792															$ 13,398																64,417,722		(61,405,345)																	3,026,567
Balance (in shares) at Dec. 31, 2018	79,246															1,409,175
Balance at Dec. 31, 2018	$ 792															$ 14,092																63,146,533		(63,107,945)																	53,472
Warrant exercises (in shares)																59,700
Warrant exercises																$ 597																5,373																			5,970
Warrants issued per bridge loan																			$ 356,471		$ 180,640	$ 6,261,590	$ 177,343															$ 356,471		$ 180,640	$ 6,261,590	$ 177,343
Vesting Expense																																2,004,366																			2,004,366
Net loss																																		(5,836,592)																	(5,836,592)
Shares issued pursuant to debt (in shares)											23,857					82,432
Shares issued pursuant to debt											$ 239					$ 824											119,135					337,749														119,374					338,573
Issuance of Series E Preferred shares (in shares)			257.7																																257.7
Issuance of Series E Preferred shares			$ 3																													2,338,837																			2,338,840
Preferred conversion to common shares pursuant to private placement agreement
Shares issued (in shares)								286,375		7,813
Shares issued								$ 2,864		$ 78														$ 2,426,844		$ 49,922									$ 2,577,000								$ 2,429,708		$ 50,000
Shares issued for acquisition (in shares)		3,500,000														400,000
Shares issued for acquisition		$ 35,000														$ 4,000																5,573,250																			5,612,250
Shares issued in forbearance agreement (in shares)																16,667
Shares issued in forbearance agreement																$ 166																158,183																			158,349
Stock issued to extinguish debt as part of Helomics purchase consideration (in shares)																863,732
Value of shares to extinguish debt (iii)																$ 8,637																6,454,672																			6,463,309
Balance (in shares) at Sep. 30, 2019	79,246	3,500,000	257.7													3,149,751
Balance at Sep. 30, 2019	$ 792	$ 35,000	$ 3													$ 31,497																89,590,908		(68,944,537)																	20,713,663
Balance (in shares) at Jun. 30, 2019	79,246	3,500,000	84.3													3,097,476
Balance at Jun. 30, 2019	$ 792	$ 35,000	$ 1													$ 30,975																87,160,845		(64,936,025)																	22,291,588
Warrant exercises (in shares)																1,844
Warrant exercises																$ 18																166																			184
Warrants issued per bridge loan																			$ 14,863	$ 60,100	$ 180,640																	$ 14,863	$ 60,100	$ 180,640
Vesting Expense																																360,146																			360,146
Net loss																																		(4,008,512)																	(4,008,512)
Shares issued pursuant to debt (in shares)											23,858					26,573
Shares issued pursuant to debt											$ 238					$ 266											$ 119,136					99,734														$ 119,374					100,000
Issuance of Series E Preferred shares (in shares)			173.4																																173.4
Issuance of Series E Preferred shares			$ 2																													1,595,278																			1,595,280
Balance (in shares) at Sep. 30, 2019	79,246	3,500,000	257.7													3,149,751
Balance at Sep. 30, 2019	$ 792	$ 35,000	$ 3													$ 31,497																$ 89,590,908		$ (68,944,537)																	$ 20,713,663

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals)	Sep. 30, 2018 $ / shares
Series E Warrants [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 10
Consulting Agreement One [Member]
Price of shares issued (in dollars per share)	11.80
Contract with TumorGenesis [Member]
Price of shares issued (in dollars per share)	11.70
TumorGenesis [Member]
Price of shares issued (in dollars per share)	11.70
Over-Allotment Option [Member]
Price of shares issued (in dollars per share)	9.497
Price of shares issued (in dollars per share)	$ 11.80

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flow from operating activities:
Net loss	$ (5,836,592)	$ (6,640,301)
Adjustments to reconcile net loss to net cash used in operating activities:
Recognition of credit loss on notes receivable	787,524
Accrued interest revenue	(34,917)
Loss on equity method investment	439,637	1,606,294
Gain on revaluation of equity method investment	(6,164,260)
Depreciation and amortization	483,631	105,569
Vesting expense	2,004,366	800,322
Equity instruments issued for management and consulting		295,000
Amortization of debt discount	1,621,181
Gain on valuation of equity-linked instruments	(84,627)
Gain on revaluation of cash advances to Helomics	(1,222,244)
Debt extinguishment costs	204,750
Loss on fixed asset disposal	293
Changes in assets and liabilities:
Accounts receivable	68,252	(101,099)
Inventories	60,638	(13,110)
Prepaid expense and other assets	33,834	70,536
Accounts payable	942,183	268,637
Accrued expenses	751,975	(470,176)
Deferred revenue	7,573	8,643
Net cash used in operating activities	(5,936,803)	(4,069,685)
Cash flow from investing activities:
Redemption of certificates of deposit		244,971
Advance on notes receivable	(975,000)	(124,774)
Cash received from notes receivable	154,418
Cash received in Helomics Acquisition	248,102
Purchase of fixed assets	(855)	(169,983)
Acquisition of intangibles	(18,419)	(46,398)
Net cash used in investing activities:	(591,754)	(96,184)
Cash flow from financing activities:
Proceeds from debt issuance	2,250,000
Repayment of debt	(609,514)
Proceeds from exercise of warrants into common stock	5,970	650,062
Proceeds from issuance of Series E convertible preferred stock	2,338,840
Issuance of common stock	2,479,708	2,959,509
Net cash provided by financing activities	6,465,004	3,609,571
Net decrease in cash and cash equivalents	(63,553)	(556,298)
Cash at beginning of period	162,152	766,189
Cash at end of period	98,599	209,891
Non-cash transactions:
Bridge loan conversion into common stock	338,573
Forbearance settlement bridge loan	503,009
Value of warrants issued (iv)	47,078
Warrants issued pursuant to debt issuance	180,640
Consideration given for acquisition of Helomics	26,711,791	1,542,250
Shares issued into escrow for TumorGenesis		877,500
Bridge loan receivable		1,815,000
Conversion of preferred stock to common stock		$ 6,479

Note 1 - Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Significant Accounting Policies [Text Block]

NOTE

– SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations and Continuance of Operations

Predictive Oncology Inc., (the “Company”) was originally incorporated on

April 23, 2002

in Minnesota as BioDrain Medical, Inc. Effective

August 6, 2013,

the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger effective

December 16, 2013,

the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware corporation as the surviving corporation of the merger. On

August 31, 2015,

the Company completed a successful offering and concurrent uplisting to the NASDAQ Capital Market. On

February 1, 2018,

the Company filed with the Secretary of State of Delaware a Certificate of Amendment to its Certificate of Incorporation to change the corporate name from Skyline Medical Inc. to Precision Therapeutics Inc., effective

February 1, 2018.

Because of this change, the Company’s common stock traded under the ticker symbol “AIPT,” effective

February 2, 2018.

June 10, 2019,

the Company filed with the Secretary of State of Delaware a Certificate of Amendment to its Certificate of Incorporation to change the corporate name from Precision Therapeutics Inc. to Predictive Oncology Inc., trading under the new ticker symbol “POAI,” effective

June 13, 2019.

Skyline Medical (“Skyline”) remains as an incorporated division of Predictive Oncology Inc. On

October 28, 2019,

the Company completed a

one

-for-

ten

reverse stock split that was effective for trading purposes on

October 29, 2019.

All numbers of shares and per-share amounts in this report have been adjusted to reflect the reverse stock split (“Reverse Split”).

The Company is a healthcare company that provides personalized medicine solution and medical devices in

two

main areas: (

) precision medicine, which aims to apply artificial intelligence to personalized medicine and drug discovery; and (

) an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of proprietary cleaning fluid and filters to users of its systems.

April 4, 2019,

the Company completed the Helomics Holding Corporation (“Helomics”) acquisition. The Company’s precision medicine services – designed to use artificial intelligence and a comprehensive disease database to improve the effectiveness of cancer therapy – were launched with the Company’s investment in Helomics. Helomics’ precision oncology services are based on its D-CHIP™ diagnostic platform, which combines a database of genomic and drug response profiles from over

149,000

tumors with an artificial intelligence based searchable bioinformatics platform. Once a patient’s tumor is excised and analyzed, the D-CHIP platform compares the tumor profile with its database, and using its extensive drug response data, provides a specific therapeutic roadmap. In addition, the Company’s wholly-owned subsidiary, TumorGenesis Inc., is developing the next generation, patient-derived tumor models for precision cancer therapy and drug development. TumorGenesis Inc., formed during the

first

quarter of

2018,

is presented as part of the unaudited condensed consolidated financial statements (“financial statements”).

The Company has incurred recurring losses from operations and has an accumulated deficit of

$68,944,537.

The Company does

not

expect to generate sufficient operating revenue to sustain its operations in the near-term. Year-to-date the Company has incurred negative cash flows from operations. Although the Company has attempted to curtail expenses, there is

guarantee that the Company will be able to reduce these expenses significantly, and expenses

may

need to be higher to prepare product lines for broader sales in order to generate sustainable revenues. The Company had cash and cash equivalents of

$98,599

as of

September 30, 2019

and needs to raise significant additional capital to meet its operating needs and pay debt obligations coming due. The Company intends to raise these funds through equity or debt financing that

may

include public offerings, private placements, alternative offerings, or other means. In the

third

quarter of

2019,

the Company raised

$1,562,840

in net proceeds from a private placement of convertible preferred stock and

$25,000

in debt financing from the Company’s CEO. The Company also completed a public offering which raised in

$2,811,309

net proceeds in

October 2019 (

see Note

). In addition, in

October 2019,

the Company entered into a purchase agreement for an equity line under which it can raise up to

$15,000,000

over a

three

-year period, subject to certain prior conditions. Despite these sources of funding, the Company will need to obtain additional financing in order to fund operations. There is substantial doubt about the Company’s ability to continue as a going concern for

one

year after the date that the financial statements are issued. The accompanying financial statements have been prepared assuming the Company will continue as a going concern and do

not

include any adjustments that might result from the outcome of this uncertainty.

Interim Financial Statements

The Company has prepared the financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations, and its cash flows for the interim periods. These interim financial statements reflect all intercompany eliminations. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Annual Report on Form

-K filed with the SEC on

April 1, 2019.

The nature of the Company’s business is such that the results of any interim period

may

not

be indicative of the results to be expected for the entire year.

Recent Accounting Developments

The Company has reviewed all recently issued accounting pronouncements and has determined that they are either

not

applicable or are

not

expected to have a material impact on its financial statements.

February 2016,

the FASB issued ASU

No.

2016

02,

“

Leases (Topic

842

)

” (“ASU

2016

02”

), which requires lessees to put most leases on their balance sheets but recognize the expenses on their income statements in a manner similar to current practice. The standard states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for the right to use the underlying asset for the lease term. The standard was effective for fiscal years and interim periods within those fiscal years beginning after

December 15, 2018.

The Company adopted the standard on

January 1, 2019,

using the transition relief to the modified retrospective approach, presenting prior year information based on the previous standard. Upon adoption, the Company recognized

$353,007

of lease right-of-use (ROU) assets and liabilities for operating leases on its condensed consolidated balance sheet, of which,

$79,252

were classified as current liabilities. The adoption of ASU

2016

did

not

have a material impact on the Company’s consolidated results of operations or cash flows.

Accounting Policies and Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities at the date of the financial statements during the reporting period. Actual results could materially differ from those estimates.

The Company leases facilities under long-term operating leases that are non-cancelable and expire on various dates. At the lease commencement date, lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term, which includes all fixed obligations arising from the lease contract. If an interest rate is

not

explicit in a lease, the Company utilizes its incremental borrowing rate for a period that closely matches the lease term.

See Note

– Leases.

Cash Equivalents

The Company considers all highly liquid debt instruments with a maturity of

three

months or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximates fair value.

Fair Value Measurements

Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification (ASC)

820,

fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC

820

establishes a

three

-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level

– Observable inputs such as quoted prices in active markets;

Level

– Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level

– Unobservable inputs where there is little or

market data, which requires the reporting entity to develop its own assumptions.

The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation.

The fair value of the Company’s investment securities was determined based on Level

inputs.

Inventories

Inventories are stated at the net realizable value, with cost determined on a

first

-in,

first

-out basis. Inventory balances are as follows:

	September 30, 2019		December 31, 2018

Finished goods	$	62,696	$	58,701
Raw materials		86,413		127,003
Work-In-Process		61,241		55,362
Total	$	210,350	$	241,066

Fixed Assets

Fixed assets are stated at cost less accumulated depreciation. Depreciation of fixed assets is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows:

	Years
Computers and office equipment	3	-	7
Leasehold improvements		2
Manufacturing tooling	3	-	7
Demo equipment		3
Laboratory equipment		4

The Company’s fixed assets consist of the following:

	September 30, 2019		December 31, 2018
Computers and office equipment	$	504,556	$	204,903
Leasehold improvements		188,014		140,114
Manufacturing tooling		108,955		108,955
Demo equipment		73,051		85,246
Laboratory equipment		1,401,210		-
Total		2,275,786		539,218
Less: Accumulated depreciation		642,036		358,765
Total Fixed Assets, Net	$	1,633,750	$	180,453

The large fluctuation in fixed assets is due to the Helomics acquisition. Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations expense as incurred.

Depreciation expense was

$130,848

and

$284,150

in the

three

and

nine

-month periods ended

September 30, 2019

and was

$26,120

and

$59,442

for the

three

and

nine

-month periods ended

September 30, 2018.

Intangible Assets

Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, and customer relationships, and are amortized over their estimated useful life. The tradename is an indefinite-lived intangible asset and is

not

amortized. Amortization expense was

$93,421

and

$199,481

in the

three

and

nine

-month periods ended

September 30, 2019

and was

$38,387

and

$46,127

in the

three

and

nine

-month periods ended

September 30, 2018.

The Company reviews finite-lived identifiable intangible assets for impairment in accordance with ASC

360

—

Property, Plant and Equipment

, whenever events or changes in circumstances indicate the carrying amount

may

not

be recoverable. Events or changes in circumstances that indicate the carrying amount

may

not

be recoverable include, but are

not

limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which the Company operates.

The large fluctuation in intangible assets during

2019

was due to the Helomics acquisition.

The components of intangible assets were as follows:

	9/30/2019							12/31/2018
	Gross Carrying Costs		Accumulated Amortization			Net Carrying Amount		Gross Carrying Costs		Accumulated Amortization			Net Carrying Amount
Patents & Trademarks	$	336,722	$	(191,950	)	$	144,772	$	318,304	$	(182,559	)	$	135,745
Licensing Fees		877,500		(92,625	)		784,875		877,500		(48,750	)		828,750
Developed Technology		2,882,000		(72,048	)		2,809,952		-		-			-
Customer Relationships		445,000		(74,166	)		370,834		-		-			-
Tradename		398,000		-			398,000		-		-			-
Total	$	4,939,222	$	(430,789	)	$	4,508,433	$	1,195,804	$	(231,309	)	$	964,495

The following table outlines the estimated future amortization expense related to intangible assets held as of

September 30, 2019:

Year ending December 31,	Expense
2019		90,985
2020		363,941
2021		363,941
2022		265,053
2023		215,609
Thereafter		2,810,904
Total		4,110,433

Goodwill

In accordance with ASC -

350,

Intangibles – Goodwill and Other,

goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of net assets acquired and represents the future economic benefits that the Company expects to achieve as a result of the acquisition. Goodwill is an indefinite-lived asset and is

not

amortized. Goodwill is

not

expected to be deductible for tax purposes. To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs a multi-step impairment test. The Company

first

assesses qualitative factors to determine if it is more likely than

not

that the carrying value of a reporting unit exceeds its estimated fair value. The Company

may

also elect to skip the qualitative testing and proceed directly to the quantitative testing. When performing quantitative testing, the Company

first

estimates the fair values of its reporting units using discounted cash flows. To determine fair values, the Company must make assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations, capital requirements and income taxes), long-term growth rates for determining terminal value and discount rates. Comparative market multiples are used to corroborate the results of the discounted cash flow test. If the fair value is less than the carrying value of the reporting unit, then the implied value of goodwill would be calculated and compared to the carrying amount of goodwill to determine whether goodwill is impaired. The Company did

not

have goodwill in

2018;

therefore,

impairment test was required. Based on qualitative factors as of

September 30, 2019,

it is more likely than

not

that goodwill is

not

impaired. The Company will conduct the

2019

goodwill impairment testing in the

fourth

quarter of

2019.

Income Taxes

The Company accounts for income taxes in accordance with ASC

740

Income Taxes

(“ASC

740”

). Under ASC

740,

deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.

There is

income tax provision in the accompanying statements of net loss due to the cumulative operating losses that indicate a

100%

valuation allowance for the deferred tax assets and state income taxes is appropriate.

The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than

not

that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified

income tax uncertainties.

Under Internal Revenue Code Section

382

certain stock transactions which significantly change ownership could limit amount of net operating carryforwards that

may

be utilized on an annual basis to offset taxable income in future periods. The Company has

not

yet performed an analysis of the annual net operating loss carryforwards and limitations that are available to be used against taxable income. Consequently, the limitation, if any, could result in the expiration of the Company’s loss carryforwards before they can be utilized. The Company has

not

analyzed net operating loss carryforwards under Section

382

to date. As a result of the Helomics acquisition, there

may

be significant limitation to the net operating loss. The Company intends to complete a Section

382

analysis in early

2020.

Tax years subsequent to

2015

remain open to examination by federal and state tax authorities.

Offering Costs

Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred.

Credit Risk

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any

one

financial institution. The Company has

credit risk concentration for cash amounts held in a single institution that are in excess of amounts issued by the Federal Deposit Insurance Corporation.

Segments

The Company has

five

operating segments: domestic sales, international sales, clinical testing revenue, contract research (“CRO”) revenue, and D-CHIP, formerly known as diagnostic revenue. The revenues earned in the diagnostic, clinical testing and CRO segments are immaterial to the total revenues earned and are currently represented in corporate/other in the table below. The segment revenues and segment net losses for the

three

and

nine

-month periods ended

September 30, 2019

are described in the table below. There are significant changes in the Company’s assets relating to the Helomics acquisition specifically in the corporate/other segment for intangibles, tangible fixed assets, and goodwill. In

2018,

substantially all the Company assets, revenues, and expenses were located or derived from operations in the United States and recorded under the domestic revenue segment.

	Three Months Ended September 30,												Nine Months Ended September 30,
	2019												2019
	Domestic			International			Corporate/Other			Total			Domestic			International			Corporate/Other			Total

Revenue	$	455,878		$	40,006		$	26,812		$	522,696		$	934,621		$	77,051		$	52,416		$	1,064,088

Segment Loss	$	(838,742	)	$	(92,398	)	$	(3,077,372	)	$	(4,008,512	)	$	(2,697,338	)	$	(289,492	)	$	(2,849,762	)	$	(5,836,592	)

	September 30, 2019										December 31, 2018
	Domestic			International			Corporate/Other		Total		Domestic		International		Corporate/Other			Total
Net Assets	$	(284,805	)	$	(10,387	)	$	21,008,855	$	20,713,663	$	628,451	$	41,377	$	(616,356	)	$	53,472

Risks and Uncertainties

The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but

not

limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the Food and Drug Administration (“FDA”), Clinical Laboratory Improvement Amendments (“CLIA”), and other governmental agencies.

Note 2 - Helomics Acquisition

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Business Combination Disclosure [Text Block]

NOTE

– HELOMICS ACQUISITION

The Company acquired

25%

of the capital stock of Helomics, in transactions in the

first

quarter of

2018.

April 4, 2019, (

the “Acquisition Date”), the Company completed a forward triangular merger with Helomics Acquisition Inc., a wholly-owned subsidiary of the Company and Helomics, acquiring the remaining

75%

of the capital stock of Helomics.

Helomics’ precision medicine services are designed to use artificial intelligence and a comprehensive disease database to improve the effectiveness of cancer therapy. Helomics’ precision oncology services are based on its D-CHIP diagnostic platform, which combines a database of genomic and drug response profiles from over

149,000

The acquisition of Helomics was accounted for as a business combination using the acquisition method of accounting. This method requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date. The fair value for the assets acquired and the liabilities assumed are based on information knowable and determined by management as of the date of this filing. The Company incurred

$656,615

in acquisition costs predominantly in legal and audit expenses.

The fair value of the consideration transferred in the acquisition has

five

components totaling

$26,711,791.

The following table summarizes the acquisition date fair values of assets acquired and liabilities assumed and the consideration transferred:

Value of shares to Helomics shareholders (i)	$	5,612,250
Value of Helomics notes receivable forgiven (ii)		2,210,381
Value of shares to extinguish debt (iii)		6,463,309
Value of warrants issued (iv)		6,261,591
Gain on revaluation of equity method investment (v)		6,164,260
Fair value of the consideration	$	26,711,791

Less assets acquired:
Cash & cash equivalents		248,102
Accounts receivable		207,769
Inventory		17,727
Prepaid expenses		15,321
Fixed assets, net		1,749,080
Intangible assets		3,725,000
Lease right of use assets		780,594

Plus liabilities assumed:
Accounts payable		2,374,596
Note Payable		303,333
Accrued expenses		363,569
Lease Liability – Net of Long-term Portion		422,126
Lease liability		358,468
Total assets acquired and liabilities assumed		(2,921,501	)

Goodwill	$	23,790,290

(i) Upon the acquisition, all outstanding shares of Helomics stock

not

already held by the Company were converted into the right to receive a proportionate share of

4,000,000

shares of common stock and

3,500,000

shares of Series D Convertible Preferred Stock of the Company. The fair value of these shares on the date of issuance was

$5,612,250;

(ii) the Company forgave notes and interest due from Helomics relating to previous cash advances equaling

$2,210,381;

(iii) the Company eliminated debt owed by Helomics to noteholders by issuing

8,637,323

shares of common stock to the noteholders, the value of the shares was

$6,463,309;

(iv) the Company issued

14,245,063

warrants in exchange for warrants to purchase

23,741,772

shares of Helomics common stock to the Helomics noteholders agreeing to extinguish or extend their notes. An additional

597,000

warrants were exchanged for warrants held by other parties; the total consideration of all the exchanged warrants was valued by using the Black Scholes method and equaled

$6,261,591;

and, (v) as the Company’s acquisition of Helomics was a business combination achieved in stages, the initial

25%

purchase of Helomics in

2018

was required to be revalued at current fair value on the Acquisition Date. Immediately prior to the Acquisition Date the recorded value of the equity method investment was zero. On the Acquisition Date the Company determined the fair value of the previous equity method investment was

$6,164,260

and recorded a gain for the same amount in order to recognize the investment at its fair value. The gain was calculated as the difference between the implied fair value of the Company’s previous equity method investment in Helomics and the recorded book value immediately prior to the acquisition date. The implied fair value was calculated based on the purchase consideration exchanged to acquire the remaining

75%

of Helomics and factoring a

10%

discount for lack of control.

The fair values of all common and preferred shares issued as consideration in the transaction was determined using the closing bid price of the Company’s common stock on

April 4, 2019.

The Company did

not

legally assume the debt extinguished on the day of the acquisition, however

three

noteholders did

not

exchange their notes for shares, and the holders agreed to extend such notes, representing

$303,333

in principal, to be due

days from the acquisition date. This portion of the debt was assumed by the Company. In order to receive the extension, the Company agreed to issue

583,003

warrants to the noteholders at an exercise price of

$1.00

per share. The warrants were accounted for under the Black Scholes accounting method.

Identifiable Intangible Assets

The Company acquired intangible assets related to trademarks for the acquired Helomics trade name with an estimated fair market value of

$398,000.

The Company expects to employ the Helomics trade name for the foreseeable future. The fair values of the assets were determined by the relief-from-royalty method under the income approach.

The Company acquired intangible assets with a useful life of

three

years and an estimated value of

$445,000

related to customer relationships stemming from stable and predictable cash flow streams associated with customers. Helomics’ customer base includes contract research partnerships with pharmaceutical, diagnostic, biotechnology, and research companies. Helomic’s existing customers are all within its CRO services business line. The customer relationships were valued using the with and without method under the income approach.

The Company acquired intangible assets with a useful life of

years and an estimated value of

$2,882,000

related to developed technology stemming from the D-CHIP diagnostic platform and underlying tumor database. Since the D-CHIP platform and underlying database was identified as the primary asset, this technology was valued using the multi-period excess earnings method under the income approach.

The acquisition costs related to the intangible assets are presented in legal and accounting expenses within general and administrative expenses in the statement of net loss.

Goodwill

The

$23,790,290

goodwill represents the excess of the consideration transferred over the fair values of assets acquired and liabilities assumed and represents the future economic benefits and synergies arising from the transaction.

None

of the goodwill is deductible for income tax purposes. Goodwill was allocated to the

three

Helomics segments.

Financial Results

The financial results of Helomics since the acquisition date have been included in the Company’s unaudited condensed consolidated statements of net loss for the quarter.

Pro Forma

The following pro forma information presents the combined results of operations of Predictive Oncology and Helomics as if the acquisition of Helomics had been completed on

January 1, 2019,

with adjustments to give effect to pro forma events that are directly attributable to the acquisition. The acquisition occurred on

April 4, 2019,

therefore, there is

difference between the pro-forma and amounts reported herein for the

three

-month period ended

September 30, 2019.

	Nine Months Ended September 30, 2019
Revenue	$	1,110,148
Net loss attributable to Predictive	$	7,249,123

The primary adjustments include the deduction of the original depreciation and amortization and the inclusion of the revalued depreciation and amortization for Helomics tangible and intangible assets. The unaudited pro forma results do

not

reflect any operating efficiencies or potential cost savings which

may

result from the consolidation of operations. Accordingly, these unaudited pro forma results are presented for informational purposes only and are

not

necessarily indicative of what the actual results of operations of the combined company would have been if the acquisition had occurred at the beginning of those respective time periods, nor are they indicative of future results of operations.

There are certain portions of purchase accounting, specifically Section

382

for

Tax Loss Carryforwards

, which take place after a company has undergone a shift in ownership, that the Company has

not

completed yet and

may

have a significant impact on the financial statements.

Note 3 - Revenue Recognition	9 Months Ended
Note 3 - Revenue Recognition	Sep. 30, 2019
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	NOTE 3 – REVENUE RECOGNITION The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. The Company has elected an accounting policy to exclude sales taxes from revenue and expenses. Revenue from Product Sales The Company has medical device revenue consisting primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. This revenue stream is reported within both the domestic and international revenue segments. The Company sells its medical device products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and acceptance of its Terms and Conditions to be a customer’s contract in all cases. Product sales for medical devices consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (a) the Company has transferred physical possession of the products, (b) the Company has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Based on the shipping terms specified in the sales agreements and purchase orders, these criteria are generally met when the products are shipped from the Company’s facilities (“FOB origin,” which is the Company’s standard shipping terms). As a result, the Company determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped. The Company may, at its discretion, negotiate different shipping terms with customers which may affect the timing of revenue recognition. The Company’s standard payment terms for its customers are generally 30 to 60 days after the Company transfers control of the product to its customer. The Company allows returns of defective disposable merchandise if the customer requests a return merchandise authorization from the Company. Customers may also purchase a maintenance plan for the medical devices from the Company, which requires the Company to service the STREAMWAY System for a period of one year subsequent to the one -year anniversary date of the original STREAMWAY System invoice. The maintenance plan is considered a separate performance obligation from the product sale, is charged separately from the product sale, and is recognized over time (ratably over the one -year period) as maintenance services are provided. A time-elapsed output method is used to measure progress because the Company transfers control evenly by providing a stand-ready service. The Company has determined that this method provides a faithful depiction of the transfer of services to its customers. All amounts billed to a customer in a sales transaction for medical devices related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. Revenue from Clinical Testing The Precision Oncology Insights are clinic diagnostic testing comprised of the Company’s ChemoFx and BioSpeciFx tests. The ChemoFx test determines how a patient’s tumor specimen reacts to a panel of various chemotherapy drugs, while the BioSpeciFx test evaluates the expression of a particular gene related to a patient’s tumor specimen. Revenues are recognized when control of the promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The estimated uncollectible amounts are generally considered implicit price concessions that are a reduction in revenue. Helomics payments terms vary by the agreements reached with insurance carriers and Medicare. The Company’s performance obligations are satisfied at one point in time when test reports are delivered. This revenue stream is reported under the clinical revenue segments (see Note 1 ). For service revenues, the Company estimates the transaction price which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for a contract with a patient, it will account for the change as an increase to the estimate of the transaction price, provided that such downward adjustment does not result in a significant reversal of cumulative revenue recognized. The Company recognizes revenue from these patients when contracts as defined in ASC 606, Revenue from Contracts with Customers are established at the amount of consideration to which it expects to be entitled or when the Company receives substantially all of the consideration subsequent to the performance obligations being satisfied. CRO Revenue Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case-by-case basis according to the facts and circumstances applicable to a given contract. The Company typically uses an input method that recognizes revenue based on the Company’s efforts to satisfy the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation on the basis of the standalone selling price of each distinct good or service in the contract. Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met. Payment terms are net 30 from the invoice date, which is sent to the customer as the Company satisfies the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. This revenue stream is reported under the CRO revenue segment (see Note 1 ). Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not contain any features that create variability in the amount or timing of revenue to be earned. Warranty The Company generally provides one -year warranties against defects in materials and workmanship on product sales and will either repair the products or provide replacements at no charge to customers. As they are considered assurance-type warranties, the Company does not account for them as separate performance obligations. Warranty reserve requirements are based on a specific assessment of the products sold with warranties where a customer asserts a claim for warranty or a product defect. Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of September 30, 2019, and December 31, 2018, accounts receivable totaled $372,119 and $232,602, respectively. The Company’s deferred revenues related primarily to maintenance plans and CRO revenue of $30,638 and $23,065 as of September 30, 2019 and December 31, 2018, respectively. Practical Expedients The Company has elected the practical expedient not to determine whether contracts with customers contain significant financing components as well as the practical expedient to recognize shipping and handling costs at point of sale.

Note 4 - Stockholders' Equity, Stock Options and Warrants

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

NOTE

– STOCKHOLDERS’ EQUITY, STOCK OPTIONS AND WARRANTS

Series D Preferred Shares

April 2019,

the Company issued

3,500,000

shares of Series D preferred stock to Helomics as part of the acquisition. Each share of Series D preferred stock is subject to automatic conversion, whereby each such share converts automatically on a

10:1

basis into a share of the Company’s common stock upon the earlier of (i) the consummation of any fundamental transaction (e.g., a consolidation or merger, the sale or lease of all or substantially all of the assets of Predictive or the purchase, tender or exchange offer of more than

50%

of the outstanding shares of voting stock of Predictive) or (ii) the

one

-year anniversary of the issuance date, which will be

April 4, 2020.

Series E Convertible Preferred Stock

June

through

September 2019,

the Company entered into a private placement securities purchase agreement with investors for shares of Series E convertible preferred stock for an aggregate purchase price of

$1,734,000

and

2,577,000

in the

three

and

nine

-month periods ended

September 30, 2019,

respectively. During the

three

and

nine

-month periods ended

September 30, 2019,

the Company issued

173.4

and

257.7

preferred shares, respectively. The preferred shares include a contingent beneficial conversion amount of

$182,000

and

$289,936

for shares issued during the

three

and

nine

-month periods ended

September 30, 2019,

respectively, representing the intrinsic value of the shares at the time of issuance. The Company determined the Series E convertible preferred stock should be classified as permanent equity and the Company is accreting the beneficial conversion feature amount to the earliest redemption date of

six

months after the initial closing of the Series E convertible preferred stock. This offering is now closed. As of

September 30, 2019,

all shares of the Series E convertible preferred stock issued remain outstanding.

Each Preferred Share Holder shall have the right at the Company’s option to be converted into

0.056857%

of the issued and outstanding shares of common stock immediately prior to conversion for each share of Series E convertible preferred stock beginning

six

months after the initial close date of

June 13, 2019.

On the date that is

months after the initial closing date, the Company has the option to convert the preferred shares into common stock upon the same terms and limitations as the above optional conversion.

Net Loss Attributable to common shareholders

The net loss attributable to common shareholders for the

three

and

nine

months ended

September 30, 2019,

reflects increases for net deemed dividends to Series E convertible preferred shareholders provided in connection with various closings totaling

$2,577,000

of the private placement of Series E convertible preferred stock. The total beneficial conversion feature (BCF) of the Series E convertible preferred stock issued was

$182,000

and

$289,936

for the closing of Series E convertible preferred stock for the

three

and

nine

months ended

September 30, 2019,

respectively.

The Series E convertible preferred stock is

not

currently redeemable because the contingency has

not

been met as of

September 30, 2019,

but it is probable that the preferred stock will be redeemable in the future. The earliest potential redemption based solely on the passage of time is

December 13, 2019

and, therefore, the carrying amount of the Series E convertible preferred stock shall be accreted from the commitment date to the redemption price as a deemed dividend. The accretion of the BCF was

$125,801

and

$146,199

for the

three

and

nine

months ended

September 30, 2019,

respectively. Since the Company does

not

have retained earnings, the amortization of the Series E convertible preferred stock discount was recorded as a deemed dividend through additional paid-in capital and net loss attributable to common shareholders in calculating basic and diluted loss per common share (see Note

Equity Incentive Plan

The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to

three

years. Options under this plan have terms ranging from

three

ten

years.

Valuation and accounting for options and warrants

The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term.

For grants of stock options and warrants issued during the quarter ended

September 30, 2019,

the Company used

1.39%

2.03%

risk free interest rate,

dividend rate,

82.4%

volatility and estimated terms of

years. Value computed using these assumptions ranged from

$3.368

$6.527

per share.

The following summarizes transactions for stock options and warrants for the periods indicated:

	Stock Options					Warrants
	Number of Shares			Average Exercise Price		Number of Shares			Average Exercise Price
Outstanding at December 31, 2017		276,498		$	19.95		195,126		$	237.40

Issued		109,886			10.13		233,615			10.67
Expired		(19,456	)		20.00		(1,071	)		1,995.53
Exercised		-			-		(65,006	)		10.00

Outstanding at December 31, 2018		366,928		$	17.03		362,664		$	41.67

Issued		366,120			7.12		1,805,943			9.36
Expired		(19,484	)		14.73		(630	)		3,258.32
Exercised		-			-		(59,700	)		0.10

Outstanding at September 30, 2019		713,564		$	11.84		2,108,277		$	15.33

Stock-based compensation expense recognized for the

three

and

nine

-month periods ended

September 30, 2019

was

$360,146

and

$2,004,366,

respectively, and for the

three

and

nine

-months periods ended

September 30, 2018

was

$339,954

and

$800,322,

respectively. The Company has

$310,403

of unrecognized compensation expense related to non-vested stock options that are expected to be recognized over the next

months.

Note 5 - Notes Receivable	9 Months Ended
Note 5 - Notes Receivable	Sep. 30, 2019
Notes to Financial Statements
Financing Receivables [Text Block]	NOTE 5 – NOTES RECEIVABLE The Company has a secured promissory note receivable from CytoBioscience for $1,112,524, plus interest paid monthly at the per annum rate of ( 8% ) on the principal amount. Unpaid principal and unpaid accrued interest on the note are due and payable on February 28, 2020. In 2019, CytoBioscience and its parent company, InventaBioTech, paid interest in the first quarter due through April 2019. The Company has not received any payments from CytoBioscience since the first quarter. The Company has evaluated the feasibility of repayment, including direct conversations with the CEO and former CEO of CytoBioscience, and has concluded that recovery of the note is in doubt and that it is probable that the Company will be unable to collect all amounts due according to the contractual terms of the receivable. The Company has secured the note with lab equipment originally valued at $1,290,000. The Company believes it will be able to raise $250,000 through the sale of this equipment and has recorded a reserve for the difference. The Company obtained a judgement against CytoBioscience and has proceeded with court proceedings to claim the collateral equipment and to attempt to recover the original balance plus interest due under the note.

Note 6 - Convertible Debt and Derivative Liability

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Convertible Debt and Derivative Liability [Text Block]

NOTE

– CONVERTIBLE DEBT AND DERIVATIVE LIABILITY

Bridge Loan

Effective

September 28, 2018,

the Company issued convertible secured promissory notes to

two

private investors in the original principal amount of an aggregate

$2,297,727

(the “bridge loan”). The bridge loan was due on

September 28, 2019.

Effective

September 27, 2019,

the bridge loan of

one

investor was paid in full. Also, effective

September 27, 2019,

the due date of the bridge loan of the other investor was extended to

December 31, 2019

in exchange for

$120,000

increase in the principal balance and

15,000

shares of the Company’s common stock. In the

third

quarter, the remaining investor converted

$100,000

of the principal balance and received

26,573

shares of the Company’s common stock. The outstanding principal balance of the bridge loan as of

September 30, 2019

was

$1,878,295.

The bridge loan accrues interest at a rate of

per annum. Upon the earlier to occur of an event of default or the filing of certain registration statements, each investor will have the right at any time thereafter to convert all or any part of its bridge loan into shares of the Company’s common stock at a conversion factor that is the lesser of a discounted

trading day average price or a set price floor. The number of conversion shares that

may

be issued is subject to an exchange cap such that the sum of (a) the total number of conversion shares plus (b) the number of inducement shares is limited to an aggregate

267,833

shares.

Promissory Note

Effective

September 27, 2019,

the Company issued a promissory note with a principal amount of

$847,500

in exchange for an investment of

$700,000.

The note is due on

March 27, 2020.

Pursuant to a security agreement between the Company and the investor, the Company has granted to the investor a security interest in its assets to secure repayment of the note. As additional consideration for the investment, the Company issued an aggregate

8,858

shares of its common stock to the investor plus warrants to acquire up to

68,237

shares of the Company’s common stock at an exercise price of

$6.210

per share. The warrant is exercisable beginning on the

sixth

month anniversary of the effective date through the

fifth

-year anniversary thereof. The note accrues interest at a rate of

per annum.

Derivative Liability

Management has concluded the bridge loan contains a conversion feature which is an embedded derivative that is required to be bifurcated and separately presented as a liability on the balance sheet. The embedded derivative’s value was determined using discounted stock price for the

trading days preceding the balance sheet date, and assuming conversion on that date as management believed it is probable that the bridge loan will be convertible based on management’s expectation that additional financing will be required. The Company recognized an unrealized gain in other expenses on the statements of net loss for the corresponding change in fair value of

$84,627

for the

nine

-month period ended

September 30, 2019.

The fair value of the derivative liability as of

September 30, 2019

was

$188,118.

The value of the embedded derivative from the bridge loan as well as the derivative included in the note payable agreements with the Company’s CEO (see Note

) were based upon level

inputs – see the Fair Value Caption in Note

The table below discloses all changes in value of those derivative liabilities during the

nine

-month period ended

September 30, 2019.

Derivative Liability Balance at December 31, 2018				Derivative Instrument Issued				Gain Recognized to Revalue Derivative Instrument at Fair Value				Adjustments to Derivative Liability for Warrants Issued				Derivative Liability Balance at September 30, 2019
$	272,745				69,722				(84,627	)			(47,078	)		$	210,762

Note 7 - Loss Per Share

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Earnings Per Share [Text Block]

NOTE

- LOSS PER SHARE

The following table presents the shares used in the basic and diluted loss per common share computations:

	Three Months Ended September 30						Nine Months Ended September 30
	2019			2018			2019			2018
Numerator:
Net loss attributable to common shareholders per common share: basic and diluted calculation	$	(4,134,313	)	$	(2,506,869	)	$	(5,982,791	)	$	(6,640,301	)

Denominator:
Weighted average common shares outstanding-basic		3,146,609			1,325,261			2,581,014			1,217,829
Effect of diluted stock options, warrants and preferred stock (1)		-			-			-			-
Weighted average common shares outstanding-diluted		3,146,609			1,325,261			2,581,014			1,217,829
Loss per common share-basic and diluted	$	(1.31	)	$	(1.89	)	$	(2.32	)	$	(5.45	)

(

) The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive:

	Three and Nine Months Ended September 30
	2019		2018
Options		713,564		344,889
Warrants		2,108,277		331,927
Convertible debt		103,734		504,770
Preferred stock: series B		7,925		7,925
Preferred stock: series D		350,000		-
Preferred stock: series E		461,503		-

Note 8 - Leases

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Lessee, Operating Leases [Text Block]

NOTE

– LEASES

The Company’s corporate offices are located in Eagan, Minnesota. The lease as amended has a

three

-year term ending

January 31, 2021.

The Company leases

5,773

square feet at this location, of which

2,945

square feet is used for office space and

2,828

is used for manufacturing.

Skyline Medical Europe’s offices are located in Belgium. The Company leases around

2,000

square feet at this location,

750

of which is used for storage and

1,250

for office space. The lease is effective through

June 14, 2027.

Helomics’ offices are located in Pittsburgh, Pennsylvania. The lease, as amended, has a

three

-year term ending

January 31, 2021.

The Company leases

17,417

square feet at this location, of which approximately

1,000

square feet are used for office space and

16,417

square feet is used for laboratory operations. The Company expects that this space will be adequate for its current office and laboratory needs.

Lease expense was

$184,046

and

$367,180

for the

three

months and

nine

months ended on

September 30, 2019

and

$27,807

and

$64,986

for the

three

and

nine

months ended on

September 30, 2018,

respectively.

The following table summarizes other information related to the Company’s operating leases:

	September 30, 2019
Weighted average remaining lease term – operating leases in years		3.06
Weighted average discount rate – operating leases		8	%

The Company’s rent obligation is as follows:

2019	$	129,546
2020		519,751
2021		117,722
2022		42,124
2023		42,966
2024 and thereafter		153,278
Total lease payments		1,005,387
Less interest		118,675
Present value of lease liabilities	$	886,712

Note 9 - Related Party Transactions	9 Months Ended
Note 9 - Related Party Transactions	Sep. 30, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 9 – RELATED PARTY TRANSACTIONS The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements. One of the Company’s directors, Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). Another Company director, Tim Krochuk, is on the supervisory board for GLG. The Company and GLG have a partnership agreement with Helomics for the purpose of bringing together their proprietary technologies to build out personalized medicine platform for the diagnosis and treatment of women’s cancer. There has been no revenue or expenses generated by this partnership to date. On May 1, 2019, Mr. Gabriel executed a one -year contract with renewable three -month periods to continue as Chief Operating Officer for TumorGenesis. Mr. Gabriel will receive $13,500 in monthly cash payments. On May 21, 2019, the Company issued a third and restated common stock purchase warrant to Dr. Carl Schwartz, the Company’s CEO, for value received in connection with the funding of all or a portion of the purchase price of his second amended and restated promissory note in the principal amount of $1,620,000. The Company has accounted for the liability to issue more warrants as a derivative liability as the exact number of warrants that will be issued was uncertain at the time of the agreement. The Company issued an additional 3,451 warrants to Dr. Schwartz under the agreement in the third quarter, which reduced the value of the derivative liability by $14,863. As of September 30, 2019, the recorded derivative liability related to the agreement was $22,644. During 2019, Dr. Schwartz advanced $300,000 to the Company. The loan earns 8% interest per annum. The due date of the loan was amended and the loan is now due December 31, 2019. No additional consideration was given for this extension. The loan is not connected to the previous note payable due to Dr. Schwartz.

Note 10 - Subsequent Events	9 Months Ended
Note 10 - Subsequent Events	Sep. 30, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 10 – SUBSEQUENT EVENTS Public Offering On October 1, 2019, the Company entered into a placement agency agreement for a public offering in which the Company sold 633,554 shares of the Company’s common stock. The offering closed on October 4, 2019. The common stock was sold at a price of $5.00 per share, resulting in gross proceeds to the Company of $3,167,769, before deducting placement agent fees and estimated offering expenses. The net offering proceeds to the Company, after deducting the placement agents’ fees and other estimated offering expenses payable by the Company, were $2,811,309. In addition, the Company granted warrants to the placement agents to purchase up to 63,355 shares of common stock, equal to 10% of the aggregate number of shares of common stock sold in the offering. The warrants have an exercise price of $6.25. Reverse Stock Split On October 28, 2019, the Company completed a one -for- ten reverse stock split that was effective for trading purposes on October 29, 2019. All numbers of shares and per-share amounts in this report have been adjusted to reflect the reverse split. Equity Line Arrangement On October 24, 2019, the Company entered into an equity purchase agreement with an investor, providing for an equity financing facility. Upon the terms and subject to the conditions in the purchase agreement, the investor is committed to purchase shares having an aggregate value of up to $15,000,000 of the Company’s common stock for a period of up to three years. The Company issued to the investor 104,651 commitment shares for entering into the agreement. From time to time during the three -year commitment period, provided that the closing conditions are satisfied, the Company may provide the investor with put notices to purchase a specified number of shares subject to certain limitations and conditions and at specified prices, which generally represent discounts to the market price of the common stock.

Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Nature of Operations and Continuance of Operations

Predictive Oncology Inc., (the “Company”) was originally incorporated on

April 23, 2002

in Minnesota as BioDrain Medical, Inc. Effective

August 6, 2013,

the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger effective

December 16, 2013,

the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware corporation as the surviving corporation of the merger. On

August 31, 2015,

the Company completed a successful offering and concurrent uplisting to the NASDAQ Capital Market. On

February 1, 2018,

February 1, 2018.

Because of this change, the Company’s common stock traded under the ticker symbol “AIPT,” effective

February 2, 2018.

June 10, 2019,

June 13, 2019.

Skyline Medical (“Skyline”) remains as an incorporated division of Predictive Oncology Inc. On

October 28, 2019,

the Company completed a

one

-for-

ten

reverse stock split that was effective for trading purposes on

October 29, 2019.

All numbers of shares and per-share amounts in this report have been adjusted to reflect the reverse stock split (“Reverse Split”).

The Company is a healthcare company that provides personalized medicine solution and medical devices in

two

main areas: (

) precision medicine, which aims to apply artificial intelligence to personalized medicine and drug discovery; and (

April 4, 2019,

149,000

first

quarter of

2018,

is presented as part of the unaudited condensed consolidated financial statements (“financial statements”).

The Company has incurred recurring losses from operations and has an accumulated deficit of

$68,944,537.

The Company does

not

guarantee that the Company will be able to reduce these expenses significantly, and expenses

may

need to be higher to prepare product lines for broader sales in order to generate sustainable revenues. The Company had cash and cash equivalents of

$98,599

as of

September 30, 2019

and needs to raise significant additional capital to meet its operating needs and pay debt obligations coming due. The Company intends to raise these funds through equity or debt financing that

may

include public offerings, private placements, alternative offerings, or other means. In the

third

quarter of

2019,

the Company raised

$1,562,840

in net proceeds from a private placement of convertible preferred stock and

$25,000

in debt financing from the Company’s CEO. The Company also completed a public offering which raised in

$2,811,309

net proceeds in

October 2019 (

see Note

). In addition, in

October 2019,

the Company entered into a purchase agreement for an equity line under which it can raise up to

$15,000,000

over a

three

one

year after the date that the financial statements are issued. The accompanying financial statements have been prepared assuming the Company will continue as a going concern and do

not

include any adjustments that might result from the outcome of this uncertainty.

Interim Financial Statements, Policy [Policy Text Block]

Interim Financial Statements

-K filed with the SEC on

April 1, 2019.

The nature of the Company’s business is such that the results of any interim period

may

not

be indicative of the results to be expected for the entire year.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Developments

The Company has reviewed all recently issued accounting pronouncements and has determined that they are either

not

applicable or are

not

expected to have a material impact on its financial statements.

February 2016,

the FASB issued ASU

No.

2016

02,

“

Leases (Topic

842

)

” (“ASU

2016

02”

December 15, 2018.

The Company adopted the standard on

January 1, 2019,

using the transition relief to the modified retrospective approach, presenting prior year information based on the previous standard. Upon adoption, the Company recognized

$353,007

of lease right-of-use (ROU) assets and liabilities for operating leases on its condensed consolidated balance sheet, of which,

$79,252

were classified as current liabilities. The adoption of ASU

2016

did

not

have a material impact on the Company’s consolidated results of operations or cash flows.

Accounting Policies and Estimates

not

explicit in a lease, the Company utilizes its incremental borrowing rate for a period that closely matches the lease term.

See Note

– Leases.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash Equivalents

The Company considers all highly liquid debt instruments with a maturity of

three

months or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximates fair value.

Fair Value Measurement, Policy [Policy Text Block]

Fair Value Measurements

Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification (ASC)

820,

fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC

820

establishes a

three

-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level

– Observable inputs such as quoted prices in active markets;

Level

– Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level

– Unobservable inputs where there is little or

market data, which requires the reporting entity to develop its own assumptions.

The fair value of the Company’s investment securities was determined based on Level

inputs.

Inventory, Policy [Policy Text Block]

Inventories

Inventories are stated at the net realizable value, with cost determined on a

first

-in,

first

-out basis. Inventory balances are as follows:

	September 30, 2019		December 31, 2018

Finished goods	$	62,696	$	58,701
Raw materials		86,413		127,003
Work-In-Process		61,241		55,362
Total	$	210,350	$	241,066

Property, Plant and Equipment, Policy [Policy Text Block]

Fixed Assets

	Years
Computers and office equipment	3	-	7
Leasehold improvements		2
Manufacturing tooling	3	-	7
Demo equipment		3
Laboratory equipment		4

The Company’s fixed assets consist of the following:

	September 30, 2019		December 31, 2018
Computers and office equipment	$	504,556	$	204,903
Leasehold improvements		188,014		140,114
Manufacturing tooling		108,955		108,955
Demo equipment		73,051		85,246
Laboratory equipment		1,401,210		-
Total		2,275,786		539,218
Less: Accumulated depreciation		642,036		358,765
Total Fixed Assets, Net	$	1,633,750	$	180,453

Depreciation expense was

$130,848

and

$284,150

in the

three

and

nine

-month periods ended

September 30, 2019

and was

$26,120

and

$59,442

for the

three

and

nine

-month periods ended

September 30, 2018.

Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Intangible Assets

not

amortized. Amortization expense was

$93,421

and

$199,481

in the

three

and

nine

-month periods ended

September 30, 2019

and was

$38,387

and

$46,127

in the

three

and

nine

-month periods ended

September 30, 2018.

The Company reviews finite-lived identifiable intangible assets for impairment in accordance with ASC

360

—

Property, Plant and Equipment

, whenever events or changes in circumstances indicate the carrying amount

may

not

be recoverable. Events or changes in circumstances that indicate the carrying amount

may

not

be recoverable include, but are

not

limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which the Company operates.

The large fluctuation in intangible assets during

2019

was due to the Helomics acquisition.

The components of intangible assets were as follows:

	9/30/2019							12/31/2018
	Gross Carrying Costs		Accumulated Amortization			Net Carrying Amount		Gross Carrying Costs		Accumulated Amortization			Net Carrying Amount
Patents & Trademarks	$	336,722	$	(191,950	)	$	144,772	$	318,304	$	(182,559	)	$	135,745
Licensing Fees		877,500		(92,625	)		784,875		877,500		(48,750	)		828,750
Developed Technology		2,882,000		(72,048	)		2,809,952		-		-			-
Customer Relationships		445,000		(74,166	)		370,834		-		-			-
Tradename		398,000		-			398,000		-		-			-
Total	$	4,939,222	$	(430,789	)	$	4,508,433	$	1,195,804	$	(231,309	)	$	964,495

The following table outlines the estimated future amortization expense related to intangible assets held as of

September 30, 2019:

Year ending December 31,	Expense
2019		90,985
2020		363,941
2021		363,941
2022		265,053
2023		215,609
Thereafter		2,810,904
Total		4,110,433

Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]

Goodwill

In accordance with ASC -

350,

Intangibles – Goodwill and Other,

not

amortized. Goodwill is

not

expected to be deductible for tax purposes. To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs a multi-step impairment test. The Company

first

assesses qualitative factors to determine if it is more likely than

not

that the carrying value of a reporting unit exceeds its estimated fair value. The Company

may

also elect to skip the qualitative testing and proceed directly to the quantitative testing. When performing quantitative testing, the Company

first

not

have goodwill in

2018;

therefore,

impairment test was required. Based on qualitative factors as of

September 30, 2019,

it is more likely than

not

that goodwill is

not

impaired. The Company will conduct the

2019

goodwill impairment testing in the

fourth

quarter of

2019.

Income Tax, Policy [Policy Text Block]

Income Taxes

The Company accounts for income taxes in accordance with ASC

740

Income Taxes

(“ASC

740”

). Under ASC

740,

There is

income tax provision in the accompanying statements of net loss due to the cumulative operating losses that indicate a

100%

valuation allowance for the deferred tax assets and state income taxes is appropriate.

not

that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified

income tax uncertainties.

Under Internal Revenue Code Section

382

certain stock transactions which significantly change ownership could limit amount of net operating carryforwards that

may

be utilized on an annual basis to offset taxable income in future periods. The Company has

not

analyzed net operating loss carryforwards under Section

382

to date. As a result of the Helomics acquisition, there

may

be significant limitation to the net operating loss. The Company intends to complete a Section

382

analysis in early

2020.

Tax years subsequent to

2015

remain open to examination by federal and state tax authorities.

Offering Costs [Policy Text Block]

Offering Costs

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Credit Risk

one

financial institution. The Company has

credit risk concentration for cash amounts held in a single institution that are in excess of amounts issued by the Federal Deposit Insurance Corporation.

Segment Reporting, Policy [Policy Text Block]

Segments

The Company has

five

three

and

nine

-month periods ended

September 30, 2019

2018,

substantially all the Company assets, revenues, and expenses were located or derived from operations in the United States and recorded under the domestic revenue segment.

	Three Months Ended September 30,												Nine Months Ended September 30,
	2019												2019
	Domestic			International			Corporate/Other			Total			Domestic			International			Corporate/Other			Total

Revenue	$	455,878		$	40,006		$	26,812		$	522,696		$	934,621		$	77,051		$	52,416		$	1,064,088

Segment Loss	$	(838,742	)	$	(92,398	)	$	(3,077,372	)	$	(4,008,512	)	$	(2,697,338	)	$	(289,492	)	$	(2,849,762	)	$	(5,836,592	)

	September 30, 2019										December 31, 2018
	Domestic			International			Corporate/Other		Total		Domestic		International		Corporate/Other			Total
Net Assets	$	(284,805	)	$	(10,387	)	$	21,008,855	$	20,713,663	$	628,451	$	41,377	$	(616,356	)	$	53,472

Risks and Uncertainties Policy [Policy Text Block]

Risks and Uncertainties

The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but

not

Note 1 - Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2019

Notes Tables

Schedule of Inventory, Current [Table Text Block]

	September 30, 2019		December 31, 2018

Finished goods	$	62,696	$	58,701
Raw materials		86,413		127,003
Work-In-Process		61,241		55,362
Total	$	210,350	$	241,066

Property Plant and Equipment Useful Life [Table Text Block]

	Years
Computers and office equipment	3	-	7
Leasehold improvements		2
Manufacturing tooling	3	-	7
Demo equipment		3
Laboratory equipment		4

Property, Plant and Equipment [Table Text Block]

	September 30, 2019		December 31, 2018
Computers and office equipment	$	504,556	$	204,903
Leasehold improvements		188,014		140,114
Manufacturing tooling		108,955		108,955
Demo equipment		73,051		85,246
Laboratory equipment		1,401,210		-
Total		2,275,786		539,218
Less: Accumulated depreciation		642,036		358,765
Total Fixed Assets, Net	$	1,633,750	$	180,453

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	9/30/2019							12/31/2018
	Gross Carrying Costs		Accumulated Amortization			Net Carrying Amount		Gross Carrying Costs		Accumulated Amortization			Net Carrying Amount
Patents & Trademarks	$	336,722	$	(191,950	)	$	144,772	$	318,304	$	(182,559	)	$	135,745
Licensing Fees		877,500		(92,625	)		784,875		877,500		(48,750	)		828,750
Developed Technology		2,882,000		(72,048	)		2,809,952		-		-			-
Customer Relationships		445,000		(74,166	)		370,834		-		-			-
Tradename		398,000		-			398,000		-		-			-
Total	$	4,939,222	$	(430,789	)	$	4,508,433	$	1,195,804	$	(231,309	)	$	964,495

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Year ending December 31,	Expense
2019		90,985
2020		363,941
2021		363,941
2022		265,053
2023		215,609
Thereafter		2,810,904
Total		4,110,433

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Three Months Ended September 30,												Nine Months Ended September 30,
	2019												2019
	Domestic			International			Corporate/Other			Total			Domestic			International			Corporate/Other			Total

Revenue	$	455,878		$	40,006		$	26,812		$	522,696		$	934,621		$	77,051		$	52,416		$	1,064,088

Segment Loss	$	(838,742	)	$	(92,398	)	$	(3,077,372	)	$	(4,008,512	)	$	(2,697,338	)	$	(289,492	)	$	(2,849,762	)	$	(5,836,592	)

	September 30, 2019										December 31, 2018
	Domestic			International			Corporate/Other		Total		Domestic		International		Corporate/Other			Total
Net Assets	$	(284,805	)	$	(10,387	)	$	21,008,855	$	20,713,663	$	628,451	$	41,377	$	(616,356	)	$	53,472

Note 2 - Helomics Acquisition (Tables)

9 Months Ended

Sep. 30, 2019

Notes Tables

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

Value of shares to Helomics shareholders (i)	$	5,612,250
Value of Helomics notes receivable forgiven (ii)		2,210,381
Value of shares to extinguish debt (iii)		6,463,309
Value of warrants issued (iv)		6,261,591
Gain on revaluation of equity method investment (v)		6,164,260
Fair value of the consideration	$	26,711,791

Less assets acquired:
Cash & cash equivalents		248,102
Accounts receivable		207,769
Inventory		17,727
Prepaid expenses		15,321
Fixed assets, net		1,749,080
Intangible assets		3,725,000
Lease right of use assets		780,594

Plus liabilities assumed:
Accounts payable		2,374,596
Note Payable		303,333
Accrued expenses		363,569
Lease Liability – Net of Long-term Portion		422,126
Lease liability		358,468
Total assets acquired and liabilities assumed		(2,921,501	)

Goodwill	$	23,790,290

Business Acquisition, Pro Forma Information [Table Text Block]

	Nine Months Ended September 30, 2019
Revenue	$	1,110,148
Net loss attributable to Predictive	$	7,249,123

Note 4 - Stockholders' Equity, Stock Options and Warrants (Tables)

9 Months Ended

Sep. 30, 2019

Notes Tables

Share-based Payment Arrangement, Activity [Table Text Block]

	Stock Options					Warrants
	Number of Shares			Average Exercise Price		Number of Shares			Average Exercise Price
Outstanding at December 31, 2017		276,498		$	19.95		195,126		$	237.40

Issued		109,886			10.13		233,615			10.67
Expired		(19,456	)		20.00		(1,071	)		1,995.53
Exercised		-			-		(65,006	)		10.00

Outstanding at December 31, 2018		366,928		$	17.03		362,664		$	41.67

Issued		366,120			7.12		1,805,943			9.36
Expired		(19,484	)		14.73		(630	)		3,258.32
Exercised		-			-		(59,700	)		0.10

Outstanding at September 30, 2019		713,564		$	11.84		2,108,277		$	15.33

Note 6 - Convertible Debt and Derivative Liability (Tables)

9 Months Ended

Sep. 30, 2019

Notes Tables

Schedule of Derivative Liabilities at Fair Value [Table Text Block]

Derivative Liability Balance at December 31, 2018				Derivative Instrument Issued				Gain Recognized to Revalue Derivative Instrument at Fair Value				Adjustments to Derivative Liability for Warrants Issued				Derivative Liability Balance at September 30, 2019
$	272,745				69,722				(84,627	)			(47,078	)		$	210,762

Note 7 - Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2019

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended September 30						Nine Months Ended September 30
	2019			2018			2019			2018
Numerator:
Net loss attributable to common shareholders per common share: basic and diluted calculation	$	(4,134,313	)	$	(2,506,869	)	$	(5,982,791	)	$	(6,640,301	)

Denominator:
Weighted average common shares outstanding-basic		3,146,609			1,325,261			2,581,014			1,217,829
Effect of diluted stock options, warrants and preferred stock (1)		-			-			-			-
Weighted average common shares outstanding-diluted		3,146,609			1,325,261			2,581,014			1,217,829
Loss per common share-basic and diluted	$	(1.31	)	$	(1.89	)	$	(2.32	)	$	(5.45	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Three and Nine Months Ended September 30
	2019		2018
Options		713,564		344,889
Warrants		2,108,277		331,927
Convertible debt		103,734		504,770
Preferred stock: series B		7,925		7,925
Preferred stock: series D		350,000		-
Preferred stock: series E		461,503		-

Note 8 - Leases (Tables)

9 Months Ended

Sep. 30, 2019

Notes Tables

Lease, Cost [Table Text Block]

	September 30, 2019
Weighted average remaining lease term – operating leases in years		3.06
Weighted average discount rate – operating leases		8	%

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

2019	$	129,546
2020		519,751
2021		117,722
2022		42,124
2023		42,966
2024 and thereafter		153,278
Total lease payments		1,005,387
Less interest		118,675
Present value of lease liabilities	$	886,712

Note 1 - Summary of Significant Accounting Policies (Details Textual)				3 Months Ended		9 Months Ended
	Oct. 28, 2019	Oct. 24, 2019 USD ($)	Oct. 04, 2019 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Jan. 01, 2019 USD ($)	Dec. 31, 2018 USD ($)
Retained Earnings (Accumulated Deficit), Ending Balance				$ (68,944,537)		$ (68,944,537)			$ (63,107,945)
Cash and Cash Equivalents, at Carrying Value, Ending Balance				98,599		98,599			162,152
Operating Lease, Right-of-Use Asset				886,712		886,712
Operating Lease, Liability, Current				500,732		500,732
Depreciation, Total				130,848	$ 26,120	284,150	$ 59,442
Amortization of Intangible Assets, Total				93,421	$ 38,387	199,481	$ 46,127
Income Tax Expense (Benefit), Total						0
Unrecognized Tax Benefits, Ending Balance				0		0
Liability for Uncertainty in Income Taxes, Current				0		$ 0
Open Tax Year						2015 2016 2017 2018
Number of Operating Segments						5
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset								$ 353,007
Operating Lease, Liability, Current								$ 79,252
Convertible Promissory Note [Member]
Proceeds from Debt, Net of Issuance Costs				25,000
Private Placement [Member]
Proceeds from Issuance or Sale of Equity, Total				$ 1,562,840
Subsequent Event [Member] \| The 2019 Offering [Member]
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs			$ 2,811,309
Subsequent Event [Member] \| Equity Line Purchase Agreement [Member] \| Investor [Member]
Issuance or Sale of Equity, Can Be Raised		$ 15,000,000
Reverse Stock Split [Member] \| Subsequent Event [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	10

Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Finished goods	$ 62,696	$ 58,701
Raw materials	86,413	127,003
Work-In-Process	61,241	55,362
Total	$ 210,350	$ 241,066

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	9 Months Ended
	Sep. 30, 2019
Leasehold Improvements [Member]
Property, plant, and equipment, useful life (Year)	2 years
Demo Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Laboratory Equipment [Member]
Property, plant, and equipment, useful life (Year)	4 years
Minimum [Member] \| Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] \| Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	3 years
Maximum [Member] \| Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	7 years
Maximum [Member] \| Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	7 years

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Property, Plant, and Equipment Gross	$ 2,275,786	$ 539,218
Less: Accumulated depreciation	642,036	358,765
Total Fixed Assets, Net	1,633,750	180,453
Office Equipment [Member]
Property, Plant, and Equipment Gross	504,556	204,903
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	188,014	140,114
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	108,955	108,955
Demo Equipment [Member]
Property, Plant, and Equipment Gross	73,051	85,246
Laboratory Equipment [Member]
Property, Plant, and Equipment Gross	$ 1,401,210

Note 1 - Summary of Significant Accounting Policies - Components of Intangible Assets (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Gross Carrying Costs	$ 4,939,222	$ 1,195,804
Accumulated Amortization	(430,789)	(231,309)
Net Carrying Amount	4,110,433	964,495
Patents and Trademarks [Member]
Gross Carrying Costs	336,722	318,304
Accumulated Amortization	(191,950)	(182,559)
Net Carrying Amount	144,772	135,745
Licensing Agreements [Member]
Gross Carrying Costs	877,500	877,500
Accumulated Amortization	(92,625)	(48,750)
Net Carrying Amount	784,875	828,750
Developed Technology Rights [Member]
Gross Carrying Costs	2,882,000
Accumulated Amortization	(72,048)
Net Carrying Amount	2,809,952
Customer Relationships [Member]
Gross Carrying Costs	445,000
Accumulated Amortization	(74,166)
Net Carrying Amount	370,834
Trade Names [Member]
Gross Carrying Costs	398,000
Accumulated Amortization
Net Carrying Amount	$ 398,000

Note 1 - Summary of Significant Accounting Policies - Estimated Future Amortization Expense (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
2019	$ 90,985
2020	363,941
2021	363,941
2022	265,053
2023	215,609
Thereafter	2,810,904
Total	$ 4,110,433	$ 964,495

Note 1 - Summary of Significant Accounting Policies - Segments (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Revenue	$ 522,696	$ 329,930	$ 1,064,088	$ 1,100,108
Segment Loss	(4,008,512)	$ (2,506,869)	(5,836,592)	$ (6,640,301)
Net Assets	20,713,663		20,713,663		$ 53,472
Domestic [Member]
Revenue	455,878		934,621
Segment Loss	(838,742)		(2,697,338)
Net Assets	(284,805)		(284,805)		628,451
International [Member]
Revenue	40,006		77,051
Segment Loss	(92,398)		(289,492)
Net Assets	(10,387)		(10,387)		41,377
Other Segments [Member]
Revenue	26,812		52,416
Segment Loss	(3,077,372)		(2,849,762)
Net Assets	$ 21,008,855		$ 21,008,855		$ (616,356)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Note 2 - Helomics Acquisition (Details Textual) - USD ($)		9 Months Ended
	Apr. 04, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Mar. 31, 2018
Stock Issued During Period, Value, Extinguishment of Debt		$ 6,463,309
Warrants Issued		47,078
Goodwill, Ending Balance		$ 23,790,290
Notes Issued to Helomics' Noteholders [Member]
Debt Instrument, Face Amount	$ 303,333
Debt Instrument, Term	90 years
Warrants Held by Noteholders [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	583,003
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1
Helomics Holding Corp. [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage					25.00%
Business Acquisition, Percentage of Voting Interests Acquired	75.00%
Business Combination, Acquisition Related Costs	$ 656,615
Business Combination, Consideration Transferred, Total	26,711,791
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	5,612,250
Business Combination, Notes and Interest Due Forgave	$ 2,210,381
Stock Issued During Period, Shares, Extinguishment of Debt	8,637,323
Stock Issued During Period, Value, Extinguishment of Debt	$ 6,463,309
Stock Issued During Period, Shares, Acquisitions	23,741,772
Warrants Issued	$ 6,261,591
Business Acquisition, Revaluation, Gain (Loss) on Acquisition	6,164,260
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	3,725,000
Goodwill, Ending Balance	23,790,290
Helomics Holding Corp. [Member] \| Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	398,000
Helomics Holding Corp. [Member] \| Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	$ 445,000
Finite-Lived Intangible Asset, Useful Life	3 years
Helomics Holding Corp. [Member] \| Developed Technology Rights [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	$ 2,882,000
Finite-Lived Intangible Asset, Useful Life	20 years
Helomics Holding Corp. [Member] \| Warrants Issued to Holders of Helomics Notes and Warrants [Member]
Class of Warrant or Right Issued During Period	14,245,063
Helomics Holding Corp. [Member] \| Warrants Held by Other Parties [Member]
Class of Warrant or Right Issued During Period	597,000
Helomics Holding Corp. [Member] \| Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	4,000,000
Helomics Holding Corp. [Member] \| Series D Convertible Preferred Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	3,500,000

Note 2 - Helomics Acquisition - Fair value of Assets and Liabilities Assumed (Details) - USD ($)		9 Months Ended
	Apr. 04, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Value of shares to extinguish debt (iii)		$ 6,463,309
Value of warrants issued (iv)		47,078
Goodwill, Ending Balance		$ 23,790,290
Helomics Holding Corp. [Member]
Value of shares to Helomics shareholders (i)	$ 5,612,250
Value of Helomics notes receivable forgiven (ii)	2,210,381
Value of shares to extinguish debt (iii)	6,463,309
Value of warrants issued (iv)	6,261,591
Business Acquisition, Revaluation, Gain (Loss) on Acquisition	6,164,260
Fair value of the consideration	26,711,791
Cash & cash equivalents	248,102
Accounts receivable	207,769
Inventory	17,727
Prepaid expenses	15,321
Fixed assets, net	1,749,080
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	3,725,000
Lease right of use assets	780,594
Accounts payable	2,374,596
Note Payable	303,333
Accrued expenses	363,569
Lease Liability – Net of Long-term Portion	422,126
Lease liability	358,468
Total assets acquired and liabilities assumed	(2,921,501)
Goodwill, Ending Balance	$ 23,790,290

Note 2 - Helomics Acquisition - Pro Forma Information (Details)	9 Months Ended
	Sep. 30, 2019 USD ($)
Revenue	$ 1,110,148
Net loss attributable to Predictive	$ 7,249,123

Note 3 - Revenue Recognition (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Maintenance Plan, Service Requirement, Period Subsequent to One Year Anniversary of Invoice	1 year
Accounts Receivable, after Allowance for Credit Loss, Current, Total	$ 372,119	$ 232,602
Contract with Customer, Liability, Current	$ 30,638	$ 23,065
Maintenance [Member]
Revenue, Performance Obligation, Timing	1 year
Minimum [Member]
Standard Payment Term for Customers	30 days
Maximum [Member]
Standard Payment Term for Customers	60 days

Note 4 - Stockholders' Equity, Stock Options and Warrants (Details Textual)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Apr. 30, 2019 shares	Sep. 30, 2019 USD ($) shares	Sep. 30, 2018 USD ($)	Sep. 30, 2019 USD ($) $ / shares shares	Sep. 30, 2018 USD ($)	Dec. 31, 2018 $ / shares
Stock Issued During Period, Value, New Issues					$ 2,755,087
Temporary Equity, Dividends, Adjustment		$ 125,801		$ 146,199
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate				0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate				82.40%
Share-based Payment Arrangement, Expense		360,146	$ 339,954	$ 2,004,366	$ 800,322
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount		$ 310,403		$ 310,403
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares				$ 7.12		$ 10.13
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition				1 year 120 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				2.03%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares				$ 6.527
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				1.39%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term				5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares				$ 3.368
Equity Incentive Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Equity Incentive Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				3 years
Series D Preferred Stock [Member]
Preferred Stock, Shares Issued, Total \| shares	3,500,000
Convertible Preferred Stock, Conversion Rate	10
Series E Convertible Preferred Stock [Member]
Convertible Preferred Stock, Conversion Rate				0.00056857
Stock Issued During Period, Value, New Issues				$ 2,577,000
Stock Issued During Period, Shares, Convertible Preferred Shares Issued \| shares		173.4		257.7
Preferred Stock, Beneficial Conversion Feature		$ 182,000		$ 289,936
Temporary Equity, Dividends, Adjustment		$ 125,801		$ 146,199

Note 4 - Stockholders' Equity, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Warrant [Member]
Number of Shares Outstanding (in shares)	362,664	195,126
Average Exercise Price Outstanding (in dollars per share)	$ 41.67	$ 237.40
Number of Shares Issued (in shares)	1,805,943	233,615
Average Exercise Price Issued (in dollars per share)	$ 9.36	$ 10.67
Number of Shares Expired (in shares)	(630)	(1,071)
Average Exercise Price Expired (in dollars per share)	$ 3,258.32	$ 1,995.53
Number of Shares Exercised (in shares)	(59,700)	(65,006)
Average Exercise Price Exercised (in dollars per share)	$ 0.10	$ 10
Number of Shares Outstanding (in shares)	2,108,277	362,664
Average Exercise Price Outstanding (in dollars per share)	$ 15.33	$ 41.67
Share-based Payment Arrangement, Option [Member]
Number of Shares Outstanding (in shares)	366,928	276,498
Average Exercise Price Outstanding (in dollars per share)	$ 17.03	$ 19.95
Number of Shares Issued (in shares)	366,120	109,886
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 7.12	$ 10.13
Number of Shares Expired (in shares)	(19,484)	(19,456)
Average Exercise Price Expired (in dollars per share)	$ 14.73	$ 20
Number of Shares Exercised (in shares)
Average Exercise Price Exercised (in dollars per share)
Average Exercise Price Exercised (in dollars per share)
Number of Shares Outstanding (in shares)	713,564	366,928
Average Exercise Price Outstanding (in dollars per share)	$ 11.84	$ 17.03

Note 5 - Notes Receivable (Details Textual) - CytoBioscience [Member] - Promissory Notes Receivable [Member]	Sep. 30, 2019 USD ($)
Financing Receivable, after Allowance for Credit Loss, Total	$ 1,112,524
Notes Receivable, Interest Rate, Stated Percentage	8.00%
Note Receivable, Collateral Value	$ 1,290,000
Note Receivable Collateral Fair Value	$ 250,000

Note 6 - Convertible Debt and Derivative Liability (Details Textual)			3 Months Ended	9 Months Ended
	Sep. 27, 2019 USD ($) $ / shares shares	Sep. 28, 2018 USD ($) shares	Sep. 30, 2019 USD ($) shares	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Dec. 31, 2018 USD ($)
Debt Conversion, Converted Instrument, Amount				$ 338,573
Bridge Loan			$ 4,470,380	4,470,380		$ 1,634,914
Derivative Liability, Total			210,762	210,762		$ 272,745
Embedded Derivative Financial Instruments [Member]
Derivative Liability, Total			$ 188,118	188,118
Warrant for Promissory Notes [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares	68,237
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 6.21
Securities Purchase Agreements [Member] \| Convertible Promissory Note [Member]
Debt Instrument, Face Amount		$ 2,297,727
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Debt Instrument, Convertible, Threshold Trading Days		20
Conversion Shares, Sum of Number of Conversion Shares Plus Inducement Shares \| shares		267,833
Securities Purchase Agreements [Member] \| Convertible Promissory Note [Member] \| Investor 1 [Member]
Debt Instrument, Increase (Decrease), Net, Total	$ 120,000
Debt Conversion, Converted Instrument, Shares Issued \| shares	15,000
Securities Purchase Agreements [Member] \| Convertible Promissory Note [Member] \| Investor 2 [Member]
Debt Conversion, Converted Instrument, Shares Issued \| shares			26,573
Debt Conversion, Converted Instrument, Amount			$ 100,000
Bridge Loan			$ 1,878,295	1,878,295
Securities Purchase Agreements [Member] \| Promissory Note [Member]
Debt Instrument, Face Amount	$ 847,500
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt Instrument, Convertible, Threshold Trading Days	20
Proceeds from Short-term Debt, Total	$ 700,000
Debt Instrument, Convertible, Number of Equity Instruments	8,858
Debt Securities, Unrealized Gain (Loss), Total				$ (84,627)

Note 6 - Convertible Debt and Derivative Liability - Change in Fair Value of Derivative Liabilities (Details)	9 Months Ended
	Sep. 30, 2019 USD ($)
Derivative liability	$ 272,745
Derivative instrument issued	69,722
Loss recognized to revalue derivative instrument at fair value	(84,627)
Adjustments to derivative liability for warrants issued	(47,078)
Derivative liability	$ 210,762

Note 7 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)

3 Months Ended

9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Net loss attributable to common shareholders per common share: basic and diluted calculation

$ (4,134,313)

$ (2,506,869)

$ (5,982,791)

$ (6,640,301)

Weighted average common shares outstanding-basic (in shares)

3,146,609

1,325,261

2,581,014

1,217,829

Effect of diluted stock options, warrants and preferred stock (1) (in shares)

^[1]

Weighted average common shares outstanding-diluted (in shares)

3,146,609

1,325,261

2,581,014

1,217,829

Loss per common share - basic and diluted (in dollars per share)

$ (1.31)

$ (1.89)

$ (2.32)

$ (5.45)

[1]

The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive: Three and Nine Months Ended September 30 2019 2018 Options 713,564 344,889 Warrants 2,108,277 331,927 Convertible debt 103,734 504,770 Preferred stock: series B 7,925 7,925 Preferred stock: series D 350,000 - Preferred stock: series E 461,503 -

Note 7 - Loss Per Share - Antidilutive Securities Excluded from the Diluted Calculations (Details) - shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities (in shares)	713,564	344,889
Warrant [Member]
Antidilutive Securities (in shares)	2,108,277	331,927
Convertible Debt Securities [Member]
Antidilutive Securities (in shares)	103,734	504,770
Series B Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)	7,925	7,925
Series D Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)	350,000
Series E Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)	461,503

Note 8 - Leases (Details Textual)	3 Months Ended		9 Months Ended
Note 8 - Leases (Details Textual)	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Jun. 15, 2018 ft²	Feb. 01, 2018 ft²	Oct. 17, 2017 ft²
Operating Lease, Expense \| $	$ 184,046	$ 27,807	$ 367,180	$ 64,986
Corporate Office, Minnesota [Member]
Lessee, Operating Lease, Term of Contract						3 years
Area of Real Estate Property						5,773
Corporate Office, Minnesota [Member] \| Office Space [Member]
Area of Real Estate Property						2,945
Corporate Office, Minnesota [Member] \| Manufacturing Facility [Member]
Area of Real Estate Property						2,828
Skyline Medical Europe’s Offices Lease [Member]
Area of Real Estate Property					2,000
Skyline Medical Europe’s Offices Lease [Member] \| Office Space [Member]
Area of Real Estate Property					1,250
Skyline Medical Europe’s Offices Lease [Member] \| Storage Space [Member]
Area of Real Estate Property					750
Helomics' Offices [Member]
Lessee, Operating Lease, Term of Contract							3 years
Area of Real Estate Property							17,417
Helomics' Offices [Member] \| Office Space [Member]
Area of Real Estate Property							1,000
Helomics' Offices [Member] \| Laboratory [Member]
Area of Real Estate Property							16,417

Note 8 - Leases - Lease Information (Details)	Sep. 30, 2019
Weighted average remaining lease term – operating leases in years (Year)	3 years 21 days
Weighted average discount rate – operating leases	8.00%

Note 8 - Leases - Rent Obligation (Details)	Sep. 30, 2019 USD ($)
2019	$ 129,546
2020	519,751
2021	117,722
2022	42,124
2023	42,966
2024 and thereafter	153,278
Total lease payments	1,005,387
Less interest	118,675
Present value of lease liabilities	$ 886,712

Note 9 - Related Party Transactions (Details Textual) - USD ($)			3 Months Ended	9 Months Ended
	May 21, 2019	May 01, 2019	Sep. 30, 2019	Sep. 30, 2019	May 30, 2019	Dec. 31, 2018
Derivative Liability, Total			$ 210,762	$ 210,762		$ 272,745
Embedded Derivative Financial Instruments [Member]
Derivative Liability, Total			$ 188,118	188,118
Director [Member]
Related Party Transaction, Monthly Cash Payment		$ 13,500
Chief Executive Officer [Member]
Proceeds from Related Party Debt	$ 1,620,000
Chief Executive Officer [Member] \| Loans From Dr. Schwartz [Member]
Proceeds from Related Party Debt				300,000
Debt Instrument, Interest Rate, Stated Percentage					8.00%
Chief Executive Officer [Member] \| Schwartz Warrant [Member]
Class of Warrant or Right Issued During Period			3,451
Chief Executive Officer [Member] \| Schwartz Warrant [Member] \| Embedded Derivative Financial Instruments [Member]
Derivative Liability, Change in Fair Value Due to Issuance of Warrants			$ 14,863
Derivative Liability, Total			$ 22,644	$ 22,644

Note 10 - Subsequent Events (Details Textual)					9 Months Ended
Note 10 - Subsequent Events (Details Textual)	Oct. 28, 2019	Oct. 24, 2019 USD ($) shares	Oct. 04, 2019 USD ($) $ / shares shares	Oct. 01, 2019 shares	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($) $ / shares
Shares Issued, Price Per Share \| $ / shares						$ 11.80
Proceeds from Issuance of Common Stock					$ 2,479,708	$ 2,959,509
Subsequent Event [Member] \| Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	10
Subsequent Event [Member] \| Right to Purchase Units [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares			63,355
Right to Purchase Units, Percentage			10.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			$ 6.25
Subsequent Event [Member] \| The 2019 Offering [Member]
Stock Issued During Period, Shares, New Issues \| shares				633,554
Shares Issued, Price Per Share \| $ / shares			$ 5
Proceeds from Issuance of Common Stock			$ 3,167,769
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs			$ 2,811,309
Subsequent Event [Member] \| Equity Line Purchase Agreement [Member] \| Investor [Member]
Issuance or Sale of Equity, Can Be Raised		$ 15,000,000
Subsequent Event [Member] \| Commitment Share [Member] \| Investor [Member]
Stock Issued During Period, Shares, New Issues \| shares		104,651